Journal of Hepatocellular Carcinoma

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "The Emerging Multiple Modality Treatment Based on Systemic Therapy for Hepatocellular Carcinoma (HCC)", organized by Guest Advisors Professor Hui-Chuan Sun, Professor Ming Kuang, Professor Hong Zhao, and Professor Arndt Vogel in the Journal of Hepatocellular Carcinoma.

Thanks to the rapid development of systemic therapy for HCC in the past 4 years, multi-modality treatments of systemic therapy combined with such aspects as surgery, TACE, transplantation, as well as related prognostic biomarkers, have become current hotspots. This Collection aims to collect valuable evidence with various perspectives to provide reference for questions frequently discussed in the clinical practice of HCC treatment. The quickly evolving systemic therapies have improved HCC patients’ survival dramatically and changed the landscape of whole-course management.

With all these systemic therapies emerging, multi-modality treatments such as systemic therapy combined with locoregional therapy, and different combinations of systemic treatment compounds with variable mechanisms, are developing quickly, followed by much discussion and controversy. However, there is not much high-level evidence helping us to make appropriate conclusions. Therefore, the Guest Advisers of this Collection, consisting of a team of experts from China as well as Germany, will review the quality and significance of the research from a relevant perspective.

Sub-topics:

• The exploration on the 2nd line therapy subsequent by new 1st line standard systemic therapy
• Novel systemic combinations for uHCC patients, as well as systemic combined with multi-modality treatment (including surgery, transplant, TACE, HAIC, RT)
• The exploration of the use of new systemic treatment options in special populations, such as Child-Pugh B, VP4, etc.
• New advances for the early and mid-stage
• Biomarkers predict the efficacy of systemic therapy

Article types:

• Original research (main)
• Review
• Expert opinion
• Case series

The deadline for submissions is 30 November 2023.

Please submit your manuscript on our website, quoting the promo code ZDHVZ to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advanced Radiation Therapy and Radiobiology for Hepatocellular Carcinoma" in the Journal of Hepatocellular Carcinoma.

Advances in systemic therapy have transformed the care of patients with hepatocellular carcinoma (HCC) in recent years, including with immunotherapy and targeted agents. Recently, stereotactic body radiation therapy (SBRT) followed by sorafenib showed an overall survival advantage over standard of care (at the time of the original study design) sorafenib. SBRT is the first local therapy for patients with advanced stage HCC to show an OS improvement over sorafenib in a phase III trial, and this Article Collection will highlight advances in the clinical delivery of radiation for this disease and new insights into the effects of radiation on the liver.

Indeed, while the advances in systemic therapy have occurred, numerous advances in radiation therapy have occurred, including with motion management technologies, image guidance systems, particle therapies, and radioenhancers. Moreover, the biological effects of radiation on HCC and other cancers has created excitement about the potential for radiation to play a role in combination with immunotherapy and other novel therapies. Understanding the clinical advances and the biological advances related to radiation for HCC is critical to development of the next generation of clinical trials that will shape how this deadly disease is managed.

In this Article Collection, we invite investigators to submit high quality original articles on (1) the clinical efficacy and benefits of radiation for HCC using modern techniques, (2) the radiobiology of HCC, (3) the effects of radiation on the non-tumor liver, and (4) markers of response to radiation in HCC. Comprehensive review articles are also welcome, but authors are encouraged to inquire about appropriateness prior to submission.

The deadline for submissions is 15 September 2023.

Please submit your manuscript on our website, quoting the promo code HGBNE to indicate that your submission is for consideration in this Article Collection.

Guest advisors

Dr. Eugene Koay, Associate Professor, MD Anderson Cancer Center

[email protected]

Dr. Eugene Koay is a physician scientist at The University of Texas MD Anderson Cancer Center, who specializes in radiation therapy for patients with hepatobiliary and pancreatic cancers, and develops applications of the physical sciences to cancer for the purposes of early detection, biomarker development, and therapeutic management. He received a Bachelor of Science in Chemical Engineering from Rice University in 2001. He completed the MD/PhD Program at Baylor College of Medicine/Rice University in 2009, with a PhD in Bioengineering. His residency training was in Radiation Oncology at The University of Texas MD Anderson Cancer Center (2009-2014). He then joined faculty at MD Anderson where he established his clinical and research foci. He leads the Cancer Physics and Engineering Laboratory at MD Anderson. The lab studies how the physical properties of tumors relate to the biological underpinnings of the disease, and recent studies describe how patient-specific parameters may be used to detect cancer earlier, predict treatment response, and improve cancer outcomes.

Dr. Jennifer Y. Wo, Associate Professor, Massachusetts General Hospital & Harvard Medical School

[email protected]

Dr. Wo is Associate Professor of Radiation Oncology at Harvard Medical School and clinical attending physician in radiation oncology at Massachusetts General Hospital. Involved in both patient care and clinical research, her research involves prospective clinical trials with advanced radiation and integration with targeted therapies. Additionally, she is interested in identification of novel biomarkers that predict outcomes to radiation or chemoradiation, and in the evaluation on prognostic and predictive factors for outcomes in gastrointestinal malignancy.

View all papers in this article collection